BPA and risk assessment

Lancet Diabetes Endocrinol. 2020 Apr;8(4):269-270. doi: 10.1016/S2213-8587(20)30070-X.

Authors

Antonia M Calafat¹, Holger M Koch²; additional coauthors

Collaborators

additional coauthors:
S S Andra, J P Antignac, A Castaño, K Choi, A Covaci, W Dekant, D R Doerge, H Frederiksen, T Göen, M Kolossa-Gehring, A Leblanc, J F Mueller, S F Nakayama, J Nassif, A St-Amand, W Völkel, M S Wolff

Affiliations

¹ Centers for Disease Control and Prevention, Atlanta, 30341 GA, USA. Electronic address: aic7@cdc.gov.
² Institute for Prevention and Occupational Medicine of the German Social Accident Insurance - Institute of the Ruhr-University Bochum (IPA), Bochum, Germany.

No abstract available

Publication types

Letter
Comment

MeSH terms

Benzhydryl Compounds*
Risk Assessment

Substances

Benzhydryl Compounds

Grants and funding

CC999999/ImCDC/Intramural CDC HHS/United States